Fouz Nour, Amid Azura, Hashim Yumi Zuhanis Has-Yun
Bioprocess and Molecular Engineering Research Unit, Department of Biotechnology Engineering, Faculty of Engineering, International Islamic University Malaysia, Kuala Lumpur, Malaysia E-mail :
Asian Pac J Cancer Prev. 2014 Jan;14(11):6709-14. doi: 10.7314/apjcp.2013.14.11.6709.
Breast cancer is a leading cause of death in women. The available chemotherapy drugs have been associated with many side effects. Bromelain has novel medicinal qualities including anti-inflammatory, anti-thrombotic, fibrinolytic and anti-cancer functions. Commercially available bromelain is obtained through tedious methods; therefore, recombinant bromelain may provide a cheaper and simpler choice with similar quality.
This study aimed to assess the effects of commercial and recombinant bromelain on the cytokinetic behavior of MCF-7 breast cancer cells and their potential as therapeutic alternatives in cancer treatment. Cytotoxic activities of commercial and recombinant bromelain were determined using (sulforhodamine) SRB assay. Next, cell viability assays were conducted to determine effects of commercial and recombinant bromelain on MCF-7 cell cytokinetic behavior. Finally, the established growth kinetic data were used to modify a model that predicts the effects of commercial and recombinant bromelain on MCF-7 cells.
Commercial and recombinant bromelain exerted strong effects towards decreasing the cell viability of MCF-7 cells with IC50 values of 5.13 μg/mL and 6.25 μg/mL, respectively, compared to taxol with an IC50 value of 0.063 μg/mL. The present results indicate that commercial and recombinant bromelain both have anti-proliferative activity, reduced the number of cell generations from 3.92 to 2.81 for commercial bromelain and to 2.86 for recombinant bromelain, while with taxol reduction was to 3.12. Microscopic observation of bromelain-treated MCF-7 cells demonstrated detachment. Inhibition activity was verified with growth rates decreased dynamically from 0.009 h-1 to 0.0059 h-1 for commercial bromelain and to 0.0063 h-1 for recombinant bromelain.
Commercial and recombinant bromelain both affect cytokinetics of MCF-7 cells by decreasing cell viability, demonstrating similar strength to taxol.
乳腺癌是女性死亡的主要原因。现有的化疗药物有许多副作用。菠萝蛋白酶具有抗炎、抗血栓形成、纤维蛋白溶解和抗癌等新的药用特性。市售菠萝蛋白酶的获取方法繁琐；因此，重组菠萝蛋白酶可能提供质量相似但更便宜、更简便的选择。
本研究旨在评估市售菠萝蛋白酶和重组菠萝蛋白酶对MCF-7乳腺癌细胞细胞动力学行为的影响及其作为癌症治疗替代疗法的潜力。使用（磺酰罗丹明）SRB法测定市售菠萝蛋白酶和重组菠萝蛋白酶的细胞毒性活性。接下来，进行细胞活力测定以确定市售菠萝蛋白酶和重组菠萝蛋白酶对MCF-7细胞细胞动力学行为的影响。最后，利用已建立的生长动力学数据修改一个预测市售菠萝蛋白酶和重组菠萝蛋白酶对MCF-7细胞影响的模型。
市售菠萝蛋白酶和重组菠萝蛋白酶对降低MCF-7细胞的细胞活力均有显著作用，其IC50值分别为5.13μg/mL和6.25μg/mL，而紫杉醇的IC50值为0.063μg/mL。目前的结果表明，市售菠萝蛋白酶和重组菠萝蛋白酶均具有抗增殖活性，市售菠萝蛋白酶使细胞代数从3.92减少到2.81，重组菠萝蛋白酶使其减少到2.86，而紫杉醇使其减少到3.12。对经菠萝蛋白酶处理的MCF-7细胞的显微镜观察显示细胞脱离。通过生长速率动态下降验证了抑制活性，市售菠萝蛋白酶的生长速率从0.009 h-1降至0.0059 h-1，重组菠萝蛋白酶的生长速率降至0.0063 h-1。
市售菠萝蛋白酶和重组菠萝蛋白酶均通过降低细胞活力影响MCF-7细胞的细胞动力学，显示出与紫杉醇相似强度的作用。
